Horizon Pharma will spend about $800 million to buy Raptor Pharmaceutical and expand its portfolio of rare disease treatments, a growing area of focus for drugmakers.
The Ireland-based drug developer said Monday that the deal will strengthen its business in the United States and provide a platform to expand in Europe and other international markets.
Horizon Pharma to pay $800M for rare disease drug developer
Aucun commentaire:
Enregistrer un commentaire